The Food and Drug Administration approved Sientra Inc.'s (Nasdaq: SIEN) PMA supplemental allowing commercialization of its OPUS-branded breast implant products lifting the stock price 93 cents to close at $11.98.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|